Idorsia Pharmaceuticals Ltd

Good afternoon, good morning to you all. This is Andrew Weiss, and I want to welcome everyone to our webcast conference call to finally discuss the full year 2023 and first quarter 24 results with you. As you may have noticed today, we've also filled your email box with other important releases regarding governance structure at IDORSEO. I will shortly hand over to our CEO, Jean-Paul Closel, and our CFO, André Muller, to give you additional color on everything we've announced today. Then, joining us for the Q&A session, we have our general manager and president of the U.S. organization, Tosh Butt, and our soon-to-be president of Eidosia UCAN region, Benjamin Limahl, who will be taking over from Jean-Yves Chatelain. Next slide, please. Before handing over the microphone, I need to remind everyone that we will be making forward-looking statements today. You have therefore been appropriately warned about the risks and opportunities of investing in IDORSA shares. With that, Jean-Paul, the floor is yours. Next slide.

Thank you, Andrew. And after 24 years, this is going to be my last webcast as a CEO. And I think it's a good time to really think of what we have achieved since the creation seven years ago of iDorcia. We did quite a lot since we brought three drugs to the market, PIVLAS, QVVIC, and TRIVIO. And also, we, during this time, we built a global marketing organization in the U.S., in the main country, in Europe, and also in Japan. And, of course, we launched QBVIC in the U.S. and in the main European countries. We created, in addition to these three products which went on the market, a late-stage pipeline, and we continued to discover new drugs and built a very strong pipeline. We also reacquired the rights of aposetantin from Johnson & Johnson. And of course, all that required funding, and we have been able up to now to pay for all these achievements. Next slide. So we are not stopping to work, and there is still a lot to do, and I would like to focus on what we need to achieve until the end of this year. First, we have to continue to increase the sales of QBVIC, and you will see that in Europe, the launch in the different countries is going on very well, and we will see strong growth for QBVIC. We need to prepare for the launch of TriView in the U.S., and we need also to continue to innovate because new products, is going to be key for also for the future of Eidosia. And clearly, and Andre will speak about that, we need to extend the cash runway since we have been able to find a solution for delaying by six months the convertible reimbursement.

Next slide.